Bristol Myers Squibb, Bain Capital form new biopharmaceutical company - NewCo Ruchika Sharma29 July 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, NewCo, focused on...
Biocon Biologics launches Nepexto in Australia Ruchika Sharma23 July 2025 11:30 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it has launched...
JnJ seeks USFDA approval for Icotrokinra to treat plaque psoriasis in adults, adolescents Ruchika Sharma22 July 2025 11:30 AM ISTIcotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson &...
Generalized Pustular Psoriasis Linked to Higher Mortality Risk Than Plaque Psoriasis: Study Medha Baranwal13 July 2025 8:30 PM ISTUSA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a significantly higher...
Lupin, Zentiva ink pact to commercialize arthritis drug Certolizumab Pegol Ruchika Sharma9 July 2025 2:58 PM ISTIt is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis.
JnJ seeks USFDA nod of Stelara for pediatric Crohn's disease Ruchika Sharma18 Jun 2025 11:58 AM ISTHorsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA (ustekinumab) for the...
Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek Ruchika Sharma26 May 2025 11:37 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has...
Icotrokinra results show significant skin clearance in patients with difficult to treat scalp, genital psoriasis: JnJ Ruchika Sharma12 May 2025 10:30 AM ISTSpring House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the...
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Johnson and Johnson Gets CDSCO Panel nod for Additional Indication of Ustekinumab solution for injection Dr. Divya Colin4 May 2025 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has granted approval to...
Revise Phase III protocol: CDSCO Panel Tells Mankind Over Roflumilast Cream Dr. Divya Colin27 April 2025 5:45 PM ISTNew Delhi: Responding to the proposal presented by Mankind Pharmaceutical to manufacture and market selective phosphodiesterase-4 inhibitor...
Psoriasis Patients at Higher Risk of Metabolic and Cardiovascular Conditions, Study Shows Medha Baranwal20 March 2025 9:00 PM ISTChina: A recent study analyzing hospitalized patients in China has highlighted the complex comorbidity patterns associated with moderate-to-severe...
